Anti-CD19 Monoclonal antibody, clone 2E4 [PerCP/Cy5.5®]

Background: Fatty acid synthetase (Fas)/Fas ligand (FasL)-dependent apoptotic pathways have been reported as being involved in the pathogenesis of drug-induced maculopapular rashes. Objective: We investigated serum soluble FasL (sFasL) levels and peripheral blood lymphocyte subtypes to discriminate maculopapular drug eruptions (MPDE) from viral exanthema (VE). Patients/methods: Children with confirmed MPDE (group I), VE (group II), and drug rashes with eosinophilia and systemic symptoms (DRESS) or drug-induced hypersensitivity syndrome (DIHS) (group III) were included. Serum sFasL levels and peripheral blood lymphocyte subtypes were analyzed in groups I- III on admission, and repeated twice (only once for group IV-controls). Results: There were no significant serum soluble FasL level differences among the groups for all the samples. In the initial samples, CD19(+) cell numbers in group II were significantly higher than in group IV, and the CD4(+) /CD8(+) ratio was higher than groups I and IV. In the second samples, CD4(+) and CD19(+) cell numbers were significantly higher in group II than group I. In the final samples, CD4(+) cell numbers in group II were significantly higher than group I and group III. CD19(+) cells numbers in group III were significantly lower than the other groups for all samples. Conclusion: Serum sFasL levels were not found to be useful in discriminating viral exanthemas from other drug rashes. The significant differences between MPDE, VE, and DRESS were high CD4(+) and CD19(+) cell-count numbers in VE but low B-cell numbers in DRESS. This might be important for discriminating VE from DRESS, and the low B-cell count in early symptoms might be a useful predictor of DRESS development. (C) 2019 SEICAP. Published by Elsevier Espana, S.L.U. All rights reserved.

BACKGROUND Hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases (PM) is considered to be feasible, safe and to improve survival. AIM To investigate whether an immune response is activated following HIPEC for PM. METHODS Six patients were enrolled in this study. Peripheral blood samples were obtained from each patient prior to (day 0) and post-procedure (day 30), and used to evaluate the number of CD3(+) total, CD3(+)/CD4(+) T-Helper, CD3(+)/CD8(+) cytotoxic T, CD3(+)/CD56(+) natural killer and CD19(+) B lymphocyte numbers, and CD4(+): CD8(+) T lymphocyte ratios. RESULTS The total numbers of CD3(+), CD3(+)/CD4(+) T-Helper, CD3(+)/CD8(+) cytotoxic T, CD3(+)/CD56(+) natural killer and CD19(+) B lymphocytes, and CD4(+): CD8(+) lymphocyte ratios were increased in all but one patient 30 d following the cytoreductive surgery-HIPEC procedure, and these increases were significant (P <= 0.05) for CD3(+)/CD4(+) T Helper and CD3(+)/CD8(+) cytotoxic T lymphocyte numbers. CONCLUSION This report provides the first evidence that HIPEC exhibits immunomodulating activity in PM patients, resulting in generalized activation of the adaptive immune response. Moreover, the majority of lymphocyte populations increased following HIPEC and continued to be elevated several weeks following the procedure, consistent with a potential authentic immunomodulating effect rather than a normal inflammatory response, to be fully characterised in future studies.